Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

fludarabine phosphate 41Peripheral Blood Stem Cell Transplantation 36Cytarabine 32Cyclophosphamide 31Whole-Body Irradiation 30Busulfan 30Tacrolimus 28Mycophenolic Acid 27Methotrexate 18Etoposide 18Cyclosporine 18Antilymphocyte Serum 16Filgrastim 15Melphalan 13Granulocyte Colony-Stimulating Factor 11Idarubicin 10Flow Cytometry 9Clofarabine 9Daunorubicin 8sargramostim 7Radiotherapy 7Mitoxantrone 7Cord Blood Stem Cell Transplantation 7Transplantation 6Thiotepa 6Sirolimus 6merphos 5fludarabine 5aldesleukin 5Vorinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Congenital Abnormalities × Calicheamicins × Clear all
NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

National Cancer Institute (NCI)

Phase 1/2 Completed
52 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡